The groundbreaking success of Sildenafil undeniably transformed the drug landscape, but investing in companies primarily reliant on generic versions presents a uncertain picture. Despite early profits were impressive, the end of patents and the rise of less expensive alternatives have weakened market share. Therefore, a thorough evaluation of curre